OX40 agonist immunotherapy expands tumor reactive CD8 T cells with a unique T cell receptor repertoire and synergizes with PDL-1 blockade to promote tumor regression
Crossref DOI link: https://doi.org/10.1186/2051-1426-2-S3-O18
Published Online: 2014-11-06
Published Print: 2014-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Moran, Amy
Polesso, Fanny
Weinberg, Andrew
Article History
First Online: 6 November 2014